Drug Interactions between abiraterone and Citracal + D
This report displays the potential drug interactions for the following 2 drugs:
- abiraterone
- Citracal + D (calcium/vitamin d)
Interactions between your drugs
No interactions were found between abiraterone and Citracal + D. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
abiraterone
A total of 401 drugs are known to interact with abiraterone.
- Abiraterone is in the drug class miscellaneous antineoplastics.
- Abiraterone is used to treat Prostate Cancer.
Citracal + D
A total of 270 drugs are known to interact with Citracal + D.
- Citracal + d is in the drug class vitamin and mineral combinations.
- Citracal + d is used to treat the following conditions:
Drug and food interactions
calcium carbonate food
Applies to: Citracal + D (calcium / vitamin d)
ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
- Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
abiraterone food
Applies to: abiraterone
ADJUST DOSING INTERVAL: Food may significantly increase the oral bioavailability of some formulations of abiraterone acetate. Compared to administration in the fasted state, abiraterone peak plasma concentration (Cmax) and systemic exposure (AUC) were approximately 7- and 5-fold higher, respectively, when a single dose of abiraterone acetate was administered with a low-fat meal (7% fat; 300 calories) and approximately 17- and 10-fold higher, respectively, when it was administered with a high-fat meal (57% fat; 825 calories). Given the normal variation in the content and composition of meals, taking abiraterone acetate with meals has the potential to result in increased and highly variable exposures. The safety of these increased exposures during multiple dosing has not been assessed. However, the abiraterone acetate 125 mg tablet, commonly marketed as Yonsa, was found to have an approximately 6.5-fold higher Cmax and 4.4-fold higher AUC when a single dose of 500 mg (4 tablets) was administered with a high-fat meal (56% - 60% fat, 900 - 1000 calories) compared to overnight fasting in healthy volunteers. These differences were not considered clinically significant for this formulation.
MANAGEMENT: Some formulations of abiraterone acetate must be taken on an empty stomach. No food should be consumed for at least two hours before and one hour after the abiraterone acetate dose. However, the abiraterone acetate 125 mg tablet, commonly marketed as Yonsa, can be taken with or without food. The manufacturer's product labeling should be consulted for specific guidance.
References
- (2011) "Product Information. Zytiga (abiraterone)." Centocor Inc
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc.
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc
- (2021) "Product Information. Zytiga (abiraterone)." Janssen Biotech, Inc.
- (2022) "Product Information. Yonsa (abiraterone)." Sun Pharmaceutical Industries
- (2023) "Product Information. Apo-Abiraterone (abiraterone)." Apotex Inc
- (2021) "Product Information. Zytiga (abiraterone)." Janssen-Cilag Pty Ltd
- (2023) "Product Information. Abiraterone (abiraterone)." Wockhardt UK Ltd
- (2023) "Product Information. Yonsa Mpred (abiraterone-methylprednisolone)." Sun Pharma ANZ Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.